Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL): exploratory analysis of the randomized, phase 3 KEYNOTE-204 study by prior lines of therapy

John Kuruvilla; Radhakrishnan Ramchandren; Armando Santoro; Ewa Paszkiewicz-Kozik; Robin Gasiorowski; Nathalie A. Johnson; Laura Maria Fogliatto; Iara Goncalves; Jose de Oliveira; Valeria Buccheri; Guilherme Fleury Perini; Neta Goldschmidt; Irina Kryachok; Naohiro Sekiguchi; Jianxin Lin; Akash Nahar; Patricia Marinello; Pier Luigi Zinzani

doi:10.1182/blood-2020-142565

Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL): exploratory analysis of the randomized, phase 3 KEYNOTE-204 study by prior lines of therapy

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A. Johnson, Laura Maria Fogliatto, Iara Goncalves, Jose de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	624
Pages (from-to)	12
Number of pages	5
Journal	Blood
Volume	136
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2020-142565
Publication status	Published - 5 Nov 2020
Externally published	Yes
Event	62nd American Society of Hematology Annual Meeting and Exposition - Virtual Duration: 5 Dec 2020 → 8 Dec 2020

Access to Document

10.1182/blood-2020-142565

Cite this

Kuruvilla, J., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N. A., Fogliatto, L. M., Goncalves, I., de Oliveira, J., Buccheri, V., Perini, G. F., Goldschmidt, N., Kryachok, I., Sekiguchi, N., Lin, J., Nahar, A., Marinello, P., & Zinzani, P. L. (2020). Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL): exploratory analysis of the randomized, phase 3 KEYNOTE-204 study by prior lines of therapy. Blood, 136(Supplement 1), 12. Article 624. https://doi.org/10.1182/blood-2020-142565

Kuruvilla, John ; Ramchandren, Radhakrishnan ; Santoro, Armando et al. / Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) : exploratory analysis of the randomized, phase 3 KEYNOTE-204 study by prior lines of therapy. In: Blood. 2020 ; Vol. 136, No. Supplement 1. pp. 12.

@article{ddf4a1cc39ab424f96240a862f7bf050,

title = "Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL): exploratory analysis of the randomized, phase 3 KEYNOTE-204 study by prior lines of therapy",

author = "John Kuruvilla and Radhakrishnan Ramchandren and Armando Santoro and Ewa Paszkiewicz-Kozik and Robin Gasiorowski and Johnson, \{Nathalie A.\} and Fogliatto, \{Laura Maria\} and Iara Goncalves and \{de Oliveira\}, Jose and Valeria Buccheri and Perini, \{Guilherme Fleury\} and Neta Goldschmidt and Irina Kryachok and Naohiro Sekiguchi and Jianxin Lin and Akash Nahar and Patricia Marinello and Zinzani, \{Pier Luigi\}",

year = "2020",

month = nov,

day = "5",

doi = "10.1182/blood-2020-142565",

language = "English",

volume = "136",

pages = "12",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "Supplement 1",

note = "62nd American Society of Hematology Annual Meeting and Exposition ; Conference date: 05-12-2020 Through 08-12-2020",

}

Kuruvilla, J, Ramchandren, R, Santoro, A, Paszkiewicz-Kozik, E, Gasiorowski, R, Johnson, NA, Fogliatto, LM, Goncalves, I, de Oliveira, J, Buccheri, V, Perini, GF, Goldschmidt, N, Kryachok, I, Sekiguchi, N, Lin, J, Nahar, A, Marinello, P & Zinzani, PL 2020, 'Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL): exploratory analysis of the randomized, phase 3 KEYNOTE-204 study by prior lines of therapy', Blood, vol. 136, no. Supplement 1, 624, pp. 12. https://doi.org/10.1182/blood-2020-142565

Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL): exploratory analysis of the randomized, phase 3 KEYNOTE-204 study by prior lines of therapy. / Kuruvilla, John; Ramchandren, Radhakrishnan; Santoro, Armando et al.
In: Blood, Vol. 136, No. Supplement 1, 624, 05.11.2020, p. 12.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL)

T2 - 62nd American Society of Hematology Annual Meeting and Exposition

AU - Kuruvilla, John

AU - Ramchandren, Radhakrishnan

AU - Santoro, Armando

AU - Paszkiewicz-Kozik, Ewa

AU - Gasiorowski, Robin

AU - Johnson, Nathalie A.

AU - Fogliatto, Laura Maria

AU - Goncalves, Iara

AU - de Oliveira, Jose

AU - Buccheri, Valeria

AU - Perini, Guilherme Fleury

AU - Goldschmidt, Neta

AU - Kryachok, Irina

AU - Sekiguchi, Naohiro

AU - Lin, Jianxin

AU - Nahar, Akash

AU - Marinello, Patricia

AU - Zinzani, Pier Luigi

PY - 2020/11/5

Y1 - 2020/11/5

U2 - 10.1182/blood-2020-142565

DO - 10.1182/blood-2020-142565

M3 - Meeting abstract

SN - 0006-4971

VL - 136

SP - 12

JO - Blood

JF - Blood

IS - Supplement 1

M1 - 624

Y2 - 5 December 2020 through 8 December 2020

ER -

Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA et al. Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL): exploratory analysis of the randomized, phase 3 KEYNOTE-204 study by prior lines of therapy. Blood. 2020 Nov 5;136(Supplement 1):12. 624. doi: 10.1182/blood-2020-142565